Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease.
Sarthak GuptaEiko YamadaHiroyuki NakamuraPaola PerezThomas Jf PranzatelliKalie DominickShyh-Ing JangMehdi AbedDaniel MartinPeter BurbeloChangYu ZhengBen FrenchIlias AlevizosZohreh KhavandgarMargaret BeachEileen PelayoBrian WalittSarfaraz A HasniMariana J KaplanMayank TandonMaria Teresa MagoneDavid E KleinerJohn A ChioriniAlan BaerBlake M WarnerPublished in: Annals of the rheumatic diseases (2024)
SjD patients' tissues exhibit increased expression of ISGs and activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi normalises this aberrant signalling at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both glandular and extraglandular symptoms. Predicated on these data, a phase Ib/IIa randomised controlled trial to treat SjD with tofacitinib was initiated.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- poor prognosis
- rheumatoid arthritis
- oxidative stress
- study protocol
- prognostic factors
- randomized controlled trial
- systemic lupus erythematosus
- cancer therapy
- big data
- disease activity
- binding protein
- drug delivery
- artificial intelligence
- long non coding rna
- ulcerative colitis